NCT07683065Recruiting
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
SEC-HOPE: A Multicenter Retrospective Cohort Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 12 Jun 2026
- Start date
- 8 Jul 2026
- Primary completion date
- 15 Jan 2027
- Lead sponsor
- Novartis Pharmaceuticals
- NCT number
- NCT07683065
What you commit to
- Study type: Observational
- Planned participants: 150
- From 8 Jul 2026 to the primary completion date, 15 Jan 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with malignant liver disease.
- Patients with a history of liver transplantation.
- Patients with alcohol use disorder.
- Patients with other chronic liver diseases.
- Patients with diseases or treatments which cause thrombocytopenia.
Other
- Patients with evidence of MASLD absence.
- Patients with decompensated cirrhosis.
- Other protocol-defined inclusion/exclusion criteria may apply.
Who the study is looking for
- Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023.
- Patients aged ≥18 years at index date.
- Patients with no prior secukinumab exposure in available EMR history.
- Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA).
- Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC).
- Patients with confirmed plaque psoriasis with or without PsA.
- Patients with at least one cardiometabolic risk factor.
- Patients with a confirmed MASLD diagnosis.
- Patients with baseline laboratory data available.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Investigative Site Coordinator of this site? Confirm its status | Badalona | Spain | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Málaga | Spain | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Valencia | Spain | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Zaragoza | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.